NCT02562898View on ClinicalTrials.gov

Ibrutinib Combined With Gemcitabine and Nab-Paclitaxel in Patients With Metastatic Pancreatic Cancer

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

October 12, 2015

Primary Completion Date

November 15, 2019

Study Completion Date

September 1, 2020

Conditions
Metastatic Pancreatic Adenocarcinoma
Interventions
DRUG

Ibrutinib

560, 840, 420, or 280mg, orally once per day - 4 week cycle

DRUG

Paclitaxel

125mg/m2 IV Day 1, 8, and 15 - 4 week cycle

DRUG

Gemcitabine

1000mg/m2 IV Day 1, 8, and 15 - 4 week cycle

Trial Locations (2)

94158

University of California, San Francisco, San Francisco

97239

Oregon Health and Science University, Portland

All Listed Sponsors
lead

Margaret Tempero

OTHER

collaborator

Stand Up To Cancer

OTHER

collaborator

Lustgarten Foundation

OTHER

NCT02562898 - Ibrutinib Combined With Gemcitabine and Nab-Paclitaxel in Patients With Metastatic Pancreatic Cancer | Biotech Hunter | Biotech Hunter